We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2009 by Hospital Universitari Son Dureta.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00999739
First Posted: October 22, 2009
Last Update Posted: November 9, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Hospital Son Llatzer
Fondo de Investigacion Sanitaria
Information provided by:
Hospital Universitari Son Dureta
  Purpose
Randomised study comparing two pneumococcal vaccination strategies in HIV-infected adults with moderate immunossupression (CD4 between 200 and 500 cells/uL and viral load under 5logs), one with conjugated heptavalent vaccine(Prevenar, Wyeth-Lederle) followed by polysaccharide vaccine 4 weeks after (Aventis-Pasteur), and two with one dose of polysaccharide vaccine. Determination of secondary effects related to both vaccines and determination of antibody concentration (ELISA) and avidity (ELISA with thiocyanate) and opsonophagocytosis killing activity against the seven serotypes included in the heptavalent vaccine before vaccination, at 4 weeks, at 8 weeks, at48 weeks and 96 weeks. A sample of 220 HIV-infected adults (110 in each group) will be needed to detect differences of 10% for a type I error o 5% for a limited population of 2500 HIV-infected adults. The main hypothesis are :the immunogenicity of pneumococcal vaccination with conjugate and polysaccharide vaccines is superior to immunogenicity induced by polysaccharide vaccination alone(antibody concentration), the avidity and opsonophagocytosis induced by two vaccines is better than the one after polysaccharide vaccine alone, both vaccinations are safe.

Condition Intervention Phase
Pneumococcal Vaccines HIV HIV Infections Biological: Prevenar and Pneumo23 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Sequential Vaccination Strategy With Conjugated and Polysaccharide Pneumococcal Vaccines Compared With Polysaccharide Vaccine in HIV- Infected Adults.

Resource links provided by NLM:


Further study details as provided by Hospital Universitari Son Dureta:

Primary Outcome Measures:
  • Antibody response in terms of antibody concentration at 4,8,48 and 69 weeks of vaccination [ Time Frame: 4, 8, 48 and 96 weeks of vaccination ]

Secondary Outcome Measures:
  • Avidity of the antibodies induced in the two vaccination groups before and at 4 ,8 , 48 and 96 weeks of vaccination [ Time Frame: 4 , 8 ,48 and 96 weeks after vaccintation ]
  • safety of both vaccines [ Time Frame: 3 days ]
  • risk factors associated to a good vaccine response [ Time Frame: 8 weeks, 48 weeks, 96 weeks ]
  • opsonophagocytic activity against the seven polysaccharides before, and after 4,8,48 and 96 weeks of vaccination [ Time Frame: 4,8,48 and 96 weeks ]

Estimated Enrollment: 220
Study Start Date: December 2007
Estimated Study Completion Date: April 2010
Estimated Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: two vaccines
people allocated to arm two vaccines will receive one dose of heptavalent pneumococcal conjugate vaccine at day 0 and 23-valent polysaccharide vaccine at week4 , 110 HIV-infected people will be included Intervention: administration of two vaccines
Biological: Prevenar and Pneumo23
Two vaccines: participants will receive via intramuscular in deltoid one dose of conjugated heptavalent vaccine at day 0 (Prevenar, Wyeth-lederle)and one dose of 23valent polysaccharide vaccine (Pneumo23, AventisPasteur)at week4 One vaccine:participants will receive only one dose of 23valent polysaccharide vaccine at day 0.
Other Names:
  • Prevenar (heptavalent conjugated pneumococcal vaccine)
  • Pneumo23 (23valent polysaccharide pneumococcal vaccine)
Experimental: One vaccine
people allocated to arm one will receive only one doses of pneumococcal polysaccharide 23-valent vaccine. 110 HIV-infected adults will be included in this arm Intervention: administration of one vaccine
Biological: Prevenar and Pneumo23
Two vaccines: participants will receive via intramuscular in deltoid one dose of conjugated heptavalent vaccine at day 0 (Prevenar, Wyeth-lederle)and one dose of 23valent polysaccharide vaccine (Pneumo23, AventisPasteur)at week4 One vaccine:participants will receive only one dose of 23valent polysaccharide vaccine at day 0.
Other Names:
  • Prevenar (heptavalent conjugated pneumococcal vaccine)
  • Pneumo23 (23valent polysaccharide pneumococcal vaccine)

Detailed Description:

Randomised study comparing two pneumococcal vaccination strategies in HIV-infected adults with moderate immunossupression (CD4 between 200 and 500 cells/uL and viral load under 5logs), one with conjugated heptavalent vaccine(Prevenar, Wyeth-Lederle) followed by polysaccharide vaccine 4 weeks after (Aventis-Pasteur), and two with one dose of polysaccharide vaccine. A sample of 220 HIV-infected adults will be randomised to receive twe strategy one(110 patients) one dose of heptavalent conjugated vaccine at day 0 and one dose of polysaccharide vaccine at week 4 (in deltoid muscle); or strategy two (110 patients) one dose of polysaccharide vaccine at day 0. Secondary effects to the vaccines will be evaluated by phone interview 3 days after vaccinations.

Blood samples will be taken at day 0(before the first vaccine), at week 4 before the polysaccharide in the group one, and 4 weeks after the polysaccharide in the group two) and at week 8 in the group one, and at weeks 48 and 96 in both groups Antibody concentration , avidity, and opsonophagocytic killing activity will be measured in all the samples for serotypes 4,14,19F,23F,6B,18C,9V.

Antibody concentration , avidity, and opsonophagocytic killing activity will be compared between both vaccine groups, and between prevaccination and at 4,8, 48 and 96 weeks of vaccination. Risk factors associated to good antibody response (antibody duplication and antibody duplication plus achieve a level above 1ug/ml)will be measured at 8, 48 and96 weeks.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV-infected adults with CD4 between 200 and 500 cels/ul and viral load under 5 logarithm

Exclusion Criteria:

  • previous pneumococcal vaccine, pregnancy, advanced renal or liver disease, other vaccine or antibiotics 6 weeks before, other immunosuppression, immunoglobulins or investigation drugs
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00999739


Contacts
Contact: maria penaranda, physician 0034971175371 maria.penaranda@ssib.es
Contact: antonio payeras, physician 0034971175371 a.payeras@hsll.es

Locations
Spain
Hospital Son Dureta Recruiting
Palma de Mallorca, Illes Balears, Spain, 07014
Contact: Maria Penaranda, physician    0034971175371    maria.penaranda@ssib.es   
Principal Investigator: maria penaranda, physician         
Hospital Son Llatzer Recruiting
Palma de Mallorca, Illes Balears, Spain, 07014
Contact: antonio payeras, physician    0037971175371    a.payeras@hsll.es   
Principal Investigator: antonio payeras, physician         
Sponsors and Collaborators
Hospital Universitari Son Dureta
Hospital Son Llatzer
Fondo de Investigacion Sanitaria
Investigators
Principal Investigator: maria penaranda, physician Hospital Son Dureta
Principal Investigator: antonio payeras, physician Hospital Son Llatzer
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Maria Penaranda, Hospital Son Dureta
ClinicalTrials.gov Identifier: NCT00999739     History of Changes
Other Study ID Numbers: Maria Penaranda
First Submitted: October 21, 2009
First Posted: October 22, 2009
Last Update Posted: November 9, 2009
Last Verified: October 2009

Keywords provided by Hospital Universitari Son Dureta:
pneumococcal vaccines
HIV
antibody response
antibody affinity
Antibody formation
Phagocytosis

Additional relevant MeSH terms:
Vaccines
Heptavalent Pneumococcal Conjugate Vaccine
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Antibodies
Immunologic Factors
Physiological Effects of Drugs